- Home
- PCRX vs CDTX Comparison
PCRX vs CDTX Comparison
Compare PCRX & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- CDTX
- Stock Information
- Founded
- PCRX 2006
- CDTX 2012
- Country
- PCRX United States
- CDTX United States
- Employees
- PCRX N/A
- CDTX N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PCRX Health Care
- CDTX Health Care
- Exchange
- PCRX Nasdaq
- CDTX Nasdaq
- Market Cap
- PCRX 1.2B
- CDTX 980.1M
- IPO Year
- PCRX 2011
- CDTX 2015
- Fundamental
- Price
- PCRX $22.07
- CDTX $62.90
- Analyst Decision
- PCRX Buy
- CDTX Strong Buy
- Analyst Count
- PCRX 8
- CDTX 11
- Target Price
- PCRX $28.38
- CDTX $52.11
- AVG Volume (30 Days)
- PCRX 590.9K
- CDTX 661.7K
- Earning Date
- PCRX 08-05-2025
- CDTX 08-07-2025
- Dividend Yield
- PCRX N/A
- CDTX N/A
- EPS Growth
- PCRX N/A
- CDTX N/A
- EPS
- PCRX N/A
- CDTX N/A
- Revenue
- PCRX $702,772,000.00
- CDTX $302,000.00
- Revenue This Year
- PCRX $7.90
- CDTX N/A
- Revenue Next Year
- PCRX $11.02
- CDTX N/A
- P/E Ratio
- PCRX N/A
- CDTX N/A
- Revenue Growth
- PCRX 3.08
- CDTX N/A
- 52 Week Low
- PCRX $11.16
- CDTX $10.14
- 52 Week High
- PCRX $27.64
- CDTX $66.95
- Technical
- Relative Strength Index (RSI)
- PCRX 44.39
- CDTX 69.50
- Support Level
- PCRX $20.85
- CDTX $60.71
- Resistance Level
- PCRX $22.32
- CDTX $64.95
- Average True Range (ATR)
- PCRX 0.84
- CDTX 3.96
- MACD
- PCRX 0.01
- CDTX -0.50
- Stochastic Oscillator
- PCRX 44.69
- CDTX 75.77
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.